SCHEMBL21588366

SCHEMBL21588366

Fc1cc(Br)ccc1N1CC2CCC(C1)O2

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 4/20 0.36
CCR2 P41597 4/20 0.36
KDM1A O60341 2/20 0.36
KDM1B Q8NB78 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.35
FPR1 P21462 1/20 0.34
FPR2 P25090 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HTT P42858 1/20 0.34
SLC6A5 Q9Y345 1/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
USP30 Q70CQ3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390773 0.81 ALDH1A1 (0.49) ALDH1A1FPR1FPR2KDM4EHTT
SCHEMBL18396772 0.81 ALDH1A1 (0.49) ALDH1A1FPR1FPR2KDM4EHTT
SCHEMBL30748794 0.81 HTT (0.54) ALDH1A1HPGDKDM4EHTTPDE3B
SCHEMBL250260 0.77 DPP4 (0.42) ALDH1A1SLC6A5USP30
SCHEMBL10232957 0.77 FPR1 (0.33) FPR1FPR2KDM4EHTTPDE3B
Hydrochloric Acid SCHEMBL249596 0.76 SLC6A2 (0.33) FPR1FPR2KDM4EHTTPDE3B
SCHEMBL30748861 0.75 KDM1A (0.40) CCR1CCR2KDM1AKDM1BALDH1A1
SCHEMBL18397562 0.75 ALDH1A1 (0.57) ALDH1A1HTTSLC6A5MAPT
SCHEMBL10278366 0.74 FPR1 (0.35) ALDH1A1HPGDFPR1FPR2KDM4E
SCHEMBL27009296 0.73 F10 (0.39) CCR1CCR2ALDH1A1HPGDPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2023-08-17 US disclosed
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2023-08-17 US disclosed
WO-2019233883-A1 TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2019-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates MAPT, MAP1LC3A, MAP1LC3B CCR1 4787/4885CCR2 4534/4885KDM1A 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.